https://variety.com/2022/digital/news/robert-kyncl-youtube-leaving-chief-business-officer-1235353708/
Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral, Lowers Price Target to $68.5
Cantor Fitzgerald downgrades Global Blood Therapeutics (NASDAQ:GBT) from Overweight to Neutral and lowers the price target from $75 to $68.5.